Prothena Corporation PLC (PRTA) Stake Boosted by Bank of Montreal Can
Bank of Montreal Can lifted its stake in Prothena Corporation PLC (NASDAQ:PRTA) by 6.7% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 1,858 shares of the biotechnology company’s stock after acquiring an additional 117 shares during the quarter. Bank of Montreal Can’s holdings in Prothena Corporation PLC were worth $100,000 at the end of the most recent reporting period.
Other hedge funds also recently modified their holdings of the company. Victory Capital Management Inc. acquired a new stake in Prothena Corporation PLC during the 1st quarter worth approximately $588,000. BlackRock Inc. lifted its holdings in Prothena Corporation PLC by 95,458.7% during the 1st quarter. BlackRock Inc. now owns 2,733,934 shares of the biotechnology company’s stock worth $152,526,000 after buying an additional 2,731,073 shares in the last quarter. OMERS ADMINISTRATION Corp acquired a new stake in Prothena Corporation PLC during the 1st quarter worth approximately $273,000. Thrivent Financial For Lutherans lifted its holdings in Prothena Corporation PLC by 15.8% during the 1st quarter. Thrivent Financial For Lutherans now owns 37,170 shares of the biotechnology company’s stock worth $2,074,000 after buying an additional 5,070 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. lifted its holdings in Prothena Corporation PLC by 12.1% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 153,857 shares of the biotechnology company’s stock worth $8,584,000 after buying an additional 16,665 shares in the last quarter.
COPYRIGHT VIOLATION NOTICE: “Prothena Corporation PLC (PRTA) Stake Boosted by Bank of Montreal Can” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://www.thecerbatgem.com/2017/09/12/prothena-corporation-plc-prta-stake-boosted-by-bank-of-montreal-can.html.
Shares of Prothena Corporation PLC (PRTA) traded up 0.46% during midday trading on Tuesday, hitting $62.73. 59,823 shares of the stock were exchanged. The firm has a 50 day moving average of $59.64 and a 200 day moving average of $55.98. The firm’s market cap is $2.40 billion. Prothena Corporation PLC has a 12-month low of $40.58 and a 12-month high of $69.53.
Prothena Corporation PLC (NASDAQ:PRTA) last posted its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.43. Prothena Corporation PLC had a negative net margin of 527.56% and a negative return on equity of 33.20%. The business had revenue of $26.81 million for the quarter, compared to analysts’ expectations of $16.08 million. During the same period in the previous year, the company posted ($1.18) earnings per share. The business’s revenue for the quarter was up 7951.1% compared to the same quarter last year. Equities analysts forecast that Prothena Corporation PLC will post ($4.52) EPS for the current fiscal year.
In other news, Director Dennis J. Selkoe sold 3,500 shares of the business’s stock in a transaction on Friday, July 7th. The shares were sold at an average price of $58.11, for a total transaction of $203,385.00. Following the transaction, the director now directly owns 6,345 shares of the company’s stock, valued at $368,707.95. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Karin L. Walker sold 5,000 shares of the business’s stock in a transaction on Monday, July 17th. The stock was sold at an average price of $64.89, for a total transaction of $324,450.00. Following the transaction, the insider now directly owns 5,000 shares in the company, valued at $324,450. The disclosure for this sale can be found here. Insiders own 3.10% of the company’s stock.
PRTA has been the topic of a number of research reports. Zacks Investment Research lowered shares of Prothena Corporation PLC from a “buy” rating to a “hold” rating in a report on Monday, May 15th. Piper Jaffray Companies reiterated a “buy” rating on shares of Prothena Corporation PLC in a report on Tuesday, May 16th. BTIG Research initiated coverage on shares of Prothena Corporation PLC in a report on Friday, May 19th. They set a “buy” rating and a $80.00 target price on the stock. ValuEngine lowered shares of Prothena Corporation PLC from a “sell” rating to a “strong sell” rating in a report on Saturday, May 27th. Finally, Oppenheimer Holdings, Inc. reiterated an “outperform” rating and set a $70.00 target price on shares of Prothena Corporation PLC in a report on Thursday, July 6th. One research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $77.58.
About Prothena Corporation PLC
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
Receive News & Stock Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related stocks with our FREE daily email newsletter.